COVID-19 testing

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investments in LivePerson, Inc. of Class Action Lawsuit and Upcoming Deadline – LPSN

Retrieved on:

Thursday, December 14, 2023

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points:

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

LPSN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that LivePerson, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on:

Thursday, December 7, 2023

LivePerson, Acquisition, COVID-19 testing, SAN, News, LPSN, Medicare, COVID-19

), the LivePerson class action lawsuit charges LivePerson and certain of its top executive officers with violations of the Securities Exchange Act of 1934.

Key Points:

), the LivePerson class action lawsuit charges LivePerson and certain of its top executive officers with violations of the Securities Exchange Act of 1934.
A lead plaintiff acts on behalf of all other class members in directing the LivePerson class action lawsuit.
The lead plaintiff can select a law firm of its choice to litigate the LivePerson class action lawsuit.
An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the LivePerson class action lawsuit.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investments in LivePerson, Inc. of Class Action Lawsuit and Upcoming Deadline – LPSN

Retrieved on:

Monday, December 4, 2023

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points:

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

LPSN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that LivePerson, Inc. Investors with Substantial Losses Have Opportunity to Lead the LivePerson Class Action Lawsuit

Retrieved on:

Saturday, December 2, 2023

LivePerson, Acquisition, COVID-19 testing, SAN, News, LPSN, Medicare, COVID-19

), the LivePerson class action lawsuit charges LivePerson and certain of its top executive officers with violations of the Securities Exchange Act of 1934.

Key Points:

), the LivePerson class action lawsuit charges LivePerson and certain of its top executive officers with violations of the Securities Exchange Act of 1934.
A lead plaintiff acts on behalf of all other class members in directing the LivePerson class action lawsuit.
The lead plaintiff can select a law firm of its choice to litigate the LivePerson class action lawsuit.
An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the LivePerson class action lawsuit.

In Vitro Diagnostic (IVD) Trends and Market Report 2023 - New Opportunities in Multiplex Testing, Next-Generation Sequencing, Artificial Intelligence and Disruptive Technologies - ResearchAndMarkets.com

Retrieved on:

Friday, December 22, 2023

Biotechnology, Science, Health, Research, Immunochemistry, Mass spectrometry, NGS, Medicine, ...Continued, COVID-19, Fad, COVID-19 testing, IVD

The "In Vitro Diagnostic (IVD) Trends and Market Update: 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "In Vitro Diagnostic (IVD) Trends and Market Update: 2023" report has been added to ResearchAndMarkets.com's offering.
In vitro diagnostic (IVD) testing is getting back to regular business and continues to be a driving force in the practice of medicine.
Trends highlighted throughout Q3 2023 include:
In IVD Trends and Market Update Report, you'll discover the following:
What's Driving Growth in the IVD Market in Q3 and the last half of 2023?
What Product Trends and New Developments Will Shape the IVD Market in the last half of 2023?

XWELL, Inc. Reports Third Quarter 2023 Results

Retrieved on:

Tuesday, November 14, 2023

NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today reported results for the third quarter ended September 30, 2023.

Key Points:

Third quarter 2023 results included non-cash goodwill and intangible asset impairment charges totaling approximately $6.8 million.
Demonstrating the effect of the Company’s cost-savings initiatives, third quarter 2023 total cost of sales decreased 43% from the same quarter in 2022 and third quarter 2023 general and administrative expenses decreased 35% from the third quarter of 2022.
Additionally, at the beginning of the third quarter of 2023, the Company began reporting operating results for HyperPointe within its XpresCheck business.
Third quarter 2023 results included non-cash impairment charges totaling approximately $6.8 million.

LPSN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that LivePerson, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on:

Saturday, December 9, 2023

Class Action Lawsuit, Professional Services, Legal, Acquisition, LivePerson, CASE, COVID-19 testing, LPSN, COVID-19, Medicare, News, Tobacco, Pharmaceutical industry

), the LivePerson class action lawsuit charges LivePerson and certain of its top executive officers with violations of the Securities Exchange Act of 1934.

Key Points:

), the LivePerson class action lawsuit charges LivePerson and certain of its top executive officers with violations of the Securities Exchange Act of 1934.
A lead plaintiff acts on behalf of all other class members in directing the LivePerson class action lawsuit.
The lead plaintiff can select a law firm of its choice to litigate the LivePerson class action lawsuit.
An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the LivePerson class action lawsuit.

Walgreens Announces Expanded COVID-19 and Flu Testing and Treatment Offerings

Retrieved on:

Thursday, December 7, 2023

Walgreens also provides various in-store and at-home testing and treatment options to help everyone stay healthy and feel better faster if they are experiencing symptoms.

Key Points:

Walgreens also provides various in-store and at-home testing and treatment options to help everyone stay healthy and feel better faster if they are experiencing symptoms.
Walgreens offers convenient rapid and PCR testing options in-store, including a “2 results in 1" rapid test for COVID-19 and influenza that costs just $19.99 and delivers results within 30 minutes.
“Prevention, testing and treatment are all important tools for managing respiratory illnesses,” said Dr. Patel.
Visit Walgreens.com/ScheduleVaccine , use the Walgreens app or call 1-800-WALGREENS to learn more and schedule an appointment today.

LPSN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that LivePerson, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on:

Monday, December 4, 2023

Class Action Lawsuit, Professional Services, Legal, Acquisition, LivePerson, CASE, COVID-19 testing, LPSN, COVID-19, Medicare, News, Tobacco, Pharmaceutical industry

), the LivePerson class action lawsuit charges LivePerson and certain of its top executive officers with violations of the Securities Exchange Act of 1934.

Key Points:

), the LivePerson class action lawsuit charges LivePerson and certain of its top executive officers with violations of the Securities Exchange Act of 1934.
A lead plaintiff acts on behalf of all other class members in directing the LivePerson class action lawsuit.
The lead plaintiff can select a law firm of its choice to litigate the LivePerson class action lawsuit.
An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the LivePerson class action lawsuit.

Curative Appoints Brandon Charles as New Chief Medical Officer

Retrieved on:

Tuesday, November 28, 2023

Dr. Brandon Charles has joined Curative as its new Chief Medical Officer.

Key Points:

Dr. Brandon Charles has joined Curative as its new Chief Medical Officer.
With over three decades of experience in healthcare, Dr. Charles will contribute to Curative's commitment to delivering innovative healthcare solutions.
from Texas Tech University Health Sciences Center and is an alumnus of the Harvard Business School.
With his expertise, business acumen, and leadership skills, Dr. Charles will support Curative's efforts to enhance the quality of healthcare for its members.